EWA
ABUS icon

EverSource Wealth Advisors’s Arbutus Biopharma ABUS Stock Holding History

EverSource Wealth Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$931 Buy
194
+58
+43% +$255 ﹤0.01% 3989
2026
Q1 		$613 Buy
136
+17
+14% +$74 ﹤0.01% 4012
2025
Q4 		$572 Hold
119
– – ﹤0.01% 3844
2025
Q3 		$540 Sell
119
-50
-30% -$184 ﹤0.01% 3929
2025
Q2 		$522 Buy
169
+87
+106% +$289 ﹤0.01% 3884
2025
Q1 		$286 Buy
+82
New +$273 ﹤0.01% 3610

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EverSource Wealth Advisors's ABUS Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Arbutus Biopharma (ABUS) stake by 43% in Q2 2026, buying an estimated $255 and bringing the position to 194 shares worth $931. The position accounts for ﹤0.01% of the portfolio, ranked #3989.

EverSource Wealth Advisors first reported a position in ABUS in Q1 2025 and has held it in 6 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • EverSource Wealth Advisors held 194 shares of Arbutus Biopharma worth $931 as of Q2 2026.
  • EverSource Wealth Advisors bought 58 Arbutus Biopharma shares in Q2 2026, an estimated $255.
  • Arbutus Biopharma made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3989 holding.
  • EverSource Wealth Advisors first reported a position in Arbutus Biopharma in Q1 2025 and has held it in 6 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.